• Loading stock data…

Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations

[#item_full_content]

Print Friendly, PDF & Email
Spread the word